Omada Health: GLP-1-Focused Telehealth Platform Users May Feel They Can Do Without

Omada Health targets enterprise GLP-1 companion care, leveraging its platform to manage high employer demand for GLP-1 drugs. 2025 revenues grew 53% to $260M; 2026 guidance implies 22% topline growth and $7–15M adjusted EBITDA. OMDA now prescribes GLP-1s, aiming to differentiate via integrated clinical, behavioral, and benefit design solutions for employers.